Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
A phase 3 trial of an investigational treatment in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
Overview
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC is a phase 3 interventional study registered as NCT06569420 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 275 participants enrolled, started 2021-12-31 and due to reach its primary completion in 2025-07-31.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shares Shanghai Fosun Pharmaceutical Industrial Development, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
- TrialFCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.